Novel therapeutic agents in ovarian cancer
- 31 October 2006
- journal article
- review article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (8), 875-886
- https://doi.org/10.1016/j.ejso.2006.03.041
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Unlocking the potential of the human genome with RNA interferenceNature, 2004
- Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 2004
- Preliminary results from a Phase II trial of EPO906 in patients with advanced refractory ovarian cancerEuropean Journal Of Cancer, 2002
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerCancer Gene Therapy, 2002
- Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2002
- Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancerEuropean Journal Of Cancer, 2001
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian CancerGynecologic Oncology, 1999
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI Journal of the National Cancer Institute, 1995
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990